Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.
about
Advances and challenges in malaria vaccine developmentImmune mechanisms in malaria: new insights in vaccine developmentA review of malaria vaccine clinical projects based on the WHO rainbow tableDrug-resistant genotypes and multi-clonality in Plasmodium falciparum analysed by direct genome sequencing from peripheral blood of malaria patientsUse of massively parallel pyrosequencing to evaluate the diversity of and selection on Plasmodium falciparum csp T-cell epitopes in Lilongwe, MalawiVaccines for malaria: how close are we?Young lives lost as B cells falter: what we are learning about antibody responses in malaria.A research agenda for malaria eradication: drugsMolecular Evolution of PvMSP3α Block II in Plasmodium vivax from Diverse Geographic OriginsA novel clade of unique eukaryotic ribonucleotide reductase R2 subunits is exclusive to apicomplexan parasitesPlasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trialImmunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium bergheiDiversity of T cell epitopes in Plasmodium falciparum circumsporozoite protein likely due to protein-protein interactions.Differing patterns of selection and geospatial genetic diversity within two leading Plasmodium vivax candidate vaccine antigens.Genetic diversity and selection in three Plasmodium vivax merozoite surface protein 7 (Pvmsp-7) genes in a Colombian population.The evolutionary dynamics of variant antigen genes in Babesia reveal a history of genomic innovation underlying host-parasite interactionContrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparumSafety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infectionsExtreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.A research agenda for malaria eradication: vaccines.Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease.Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications.Distinct patterns of diversity, population structure and evolution in the AMA1 genes of sympatric Plasmodium falciparum and Plasmodium vivax populations of Papua New Guinea from an area of similarly high transmissionA prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarrayLimited variation in vaccine candidate Plasmodium falciparum Merozoite Surface Protein-6 over multiple transmission seasonsThe Jeremiah Metzger lecture: new additions to the toolbox for global malaria eradication.Strategies for designing and monitoring malaria vaccines targeting diverse antigensLack of allele-specific efficacy of a bivalent AMA1 malaria vaccineAllelic Forms of Merozoite Surface Protein-3 in Plasmodium falciparum Isolates From Southeast of Iran.Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 proteinA microarray platform and novel SNP calling algorithm to evaluate Plasmodium falciparum field samples of low DNA quantity.Transcriptome sequencing and analysis of Plasmodium gallinaceum reveals polymorphisms and selection on the apical membrane antigen-1.Multiple antigen peptide vaccines against Plasmodium falciparum malariaLow genetic diversity in the locus encoding the Plasmodium vivax P41 protein in Colombia's parasite population.Effects of transmission reduction by insecticide-treated bed nets (ITNs) on parasite genetics population structure: I. The genetic diversity of Plasmodium falciparum parasites by microsatellite markers in western KenyaPlasmodium falciparum field isolates from South America use an atypical red blood cell invasion pathway associated with invasion ligand polymorphisms.Genetic diversity of polymorphic vaccine candidate antigens (apical membrane antigen-1, merozoite surface protein-3, and erythrocyte binding antigen-175) in Plasmodium falciparum isolates from western and central Africa.Malaria immunoepidemiology in low transmission: correlation of infecting genotype and immune response to domains of Plasmodium falciparum merozoite surface protein 3The case for a rational genome-based vaccine against malaria.
P2860
Q21032463-8A7484CE-DBE7-4ABD-B408-D1213AFE3094Q21032484-99435504-A694-47E0-A2F8-B4F6B480867FQ21034112-85E95DB3-E67B-4D60-AA23-F38B9EA75EC1Q21091002-CFDD6A82-F626-42A2-BCD2-45D074CB136FQ24617275-07AA641B-5F04-4B81-991E-F955D12DE8FCQ27024344-7F416288-AD37-43DF-B325-C573B8A55032Q27687235-04A674B2-B922-4A69-AED4-F691763536CBQ28476806-2004526D-310A-43BA-B990-2FD1BA23EE2FQ28611284-2296CBF5-7DC2-40A5-96F9-14A43362C9EBQ28661662-A8720D9D-9B5C-47E9-AE19-AC5ED7E263EFQ28748765-0962DE1D-C7A3-47A5-95B3-86DD8452F122Q28749621-DD591873-3A44-4343-AFA1-ED73B56F2272Q30430387-CFA0E49D-F606-4A0B-9E60-1920DF3EE582Q30439881-28CFB7CB-314B-4203-8B2D-4ABE925244A8Q31103027-BFEAC978-1212-47A1-AD58-66C871566A38Q31160341-2AC75824-03B8-42C7-94E4-6020F0F018C8Q33521214-4FBE9CDA-9478-4CC3-987E-88997CF0153DQ33530106-0E69CC09-CCF3-40DF-8EA4-AA574E28368BQ33587496-FF0C2655-CC1A-42A7-BE83-302678FA2FA3Q33654911-7EC6106F-7BBE-4D2F-8EAA-B262962D4061Q33818046-630DEED9-49C4-4123-B5BA-358140C2EC34Q33821137-D87B86B7-0ECD-4C99-99BC-405C2F5AE2E6Q33846126-C4E3F3C7-019E-49F7-80DC-F427165B60B0Q33859217-1A43B2E0-4DC9-45CD-B9AD-1BD24724CFFEQ33859633-2F5E8235-4FFA-46D4-BC05-9D2ACF521873Q33898582-EE2B1A1E-083E-46DF-BC2A-7A34E955F0C3Q33957657-8E851D18-6AC7-472E-9472-3E5AF7F11E4BQ33959038-3F40A85D-3530-45D7-9AF0-5C7C25388DBBQ34011922-33164CB1-B99B-4F89-A823-16A697307B9BQ34068587-2A572115-38A5-497C-9233-533146D1A1ABQ34128586-BEA06080-B193-4AC0-97AB-A0759C8193EBQ34130050-EAA80500-5663-4A2B-8DFA-586A9158EBBFQ34278814-CE3266BA-5CF2-4148-A8E1-0F05EDCF2917Q34290800-0E544374-2BA4-4415-A34C-21872B357D79Q34309657-61474AA6-2C0D-4454-B1AD-1EBEDC93735DQ34419543-D32A86AB-C1F9-44DA-95FA-B2BCCC546F92Q34464648-D35D0C93-72E7-454E-B03B-E476E51F1BEFQ34531250-0B7C1706-7E0B-4083-A9F1-CF9633EEFDC2Q34931887-E88362A9-6D12-4E1E-A59E-818A5CC16C62Q34999392-98AA732B-C571-4C0C-BCAC-B0D5F1C460D6
P2860
Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genetic diversity and malaria ...... g 'vaccine resistant malaria'.
@en
Genetic diversity and malaria ...... g 'vaccine resistant malaria'.
@nl
type
label
Genetic diversity and malaria ...... g 'vaccine resistant malaria'.
@en
Genetic diversity and malaria ...... g 'vaccine resistant malaria'.
@nl
prefLabel
Genetic diversity and malaria ...... g 'vaccine resistant malaria'.
@en
Genetic diversity and malaria ...... g 'vaccine resistant malaria'.
@nl
P2860
P1433
P1476
Genetic diversity and malaria ...... g 'vaccine resistant malaria'.
@en
P2093
P2860
P304
P356
10.1111/J.1365-3024.2009.01138.X
P577
2009-09-01T00:00:00Z